1. Introduction {#sec1}
===============

Breast cancer is the second most common cancer in the world and by far the most frequent cancer among women with an estimated 1.67 million new cancer cases diagnosed in 2012 (25% of all cancers), and it ranks as the fifth cause of death from cancer overall (522,000 deaths) \[[@B1]\]. In 2013, breast cancer is the most prevalent malignant cancer and the fifth leading cause of cancer death in Chinese women \[[@B2], [@B3]\]. It has also been predicted by the International Agency for Research on Cancer that in 2020 the incidence and mortality of breast cancer in China would be 215,800 and 57,500, respectively \[[@B4]\].

Patient reported outcomes measures (PROMs), especially health-related quality of life (HRQOL) instruments, have increasingly been collected in randomised controlled trials (RCTs) to inform patient-centered care, clinical decision-making, and health policy or reimbursement decisions \[[@B5], [@B6]\]. Compared with the traditional assessment of clinical outcomes, HRQOL information plays an important role in breast cancer research \[[@B7]\]. Being diagnosed and living with breast cancer are a very stressful experience that may negatively affect multiple aspects of an individual\'s HRQOL and can have a long-term effect on HRQOL after treatment \[[@B8]--[@B10]\].

Along with the increasing number of breast cancer patients and the longer survival due to early detection programs and advancement in medical technology, accurately assessing HRQOL of breast cancer patients is crucial \[[@B11], [@B12]\]. By far, one of the most popular cancer-specific HRQOL instruments is the European Organization for Research and Treatment (EORTC) Quality of Life Questionnaire-C30 (QLQ-C30) \[[@B13]\]. The QLQ-C30 also has additional modules which can be used to address aspects which are of particular importance to patients with specific cancers. The breast cancer-specific module QLQ-BR23, a supplement to the general cancer questionnaire QLQ-C30, was developed to identify unique concerns to breast cancer patients \[[@B14]\].

Internationally, there are several studies assessing the HRQOL among breast cancer patients using the EORTC QLQ-C30 and QLQ-BR23 \[[@B7], [@B15]--[@B17]\]. The simplified Chinese versions of the above two questionnaires, which are commonly referred to as EORTC QLQ-BR53, have been validated in mainland China, demonstrating the validity, reliability and responsiveness in breast cancer patients \[[@B18], [@B19]\]. Although the QLQ-BR23 was developed to be used as an extension of the QLQ-C30; the literature is mixed as to whether to use both or either one of them in breast cancer patients \[[@B20]\].

The aims of this study are twofold: firstly, to explore which dimensions of HRQOL play more important roles in breast cancer patients\' overall quality of life in China and, secondly, to explore the latent factor structure and the potential complementary relationship between these two EORTC questionnaires in breast cancer patients.

2. Patients and Methods {#sec2}
=======================

2.1. Patients {#sec2.1}
-------------

Participants were recruited from women breast cancer patients who have been treated in Qingdao Municipal Hospital, China, between October 2014 and February 2015. A total of 621 female breast cancer patients who underwent inpatient treatment from the oncology wards were interviewed. Patients clearly diagnosed with breast cancer and more than 18 years old were selected as an inclusion criterion. The exclusion criterions were as follows: (1) being unwilling to give an informed consent or (2) being unable to understand the questionnaires, or (3) being combined with other serious chronic diseases, such as cardiovascular or cerebrovascular diseases, psychosis, or (4) being younger than 18 years old at the time of the survey. Informed consent was obtained from all participants after a detailed explanation of the study. Ethical approval was obtained from the Ethics Review Board of the School of Public Health, Shandong University (Reference No. 20131002), and the research adhered to the tenets of the Declaration of Helsinki.

2.2. Tools and Measures {#sec2.2}
-----------------------

The participants were interviewed face to face one day prior to discharge. During the interview, information on sociodemographic characteristics of the participants was obtained, while the clinical information was collected by the interviewer based on the medical records. The HRQOL was self-assessed by each patient using the simplified Chinese version of the EORTC QLQ-BR53 questionnaires.

The EORTC QLQ-C30 is a reliable and valid questionnaire developed to assess the quality of life (QOL) of cancer patients, which has been translated and validated in over 100 languages and is used in more than 3,000 studies worldwide \[[@B21]\]. QLQ-C30 consists of 30 items (coded Q1-Q30), including a global health status (GHS)/QOL scale, five multi-item functional subscales (physical /role /emotional /cognitive /social functioning), and several single/multi-item symptomatic subscales (fatigue /nausea and vomiting /pain /dyspnoea /insomnia /appetite loss /constipation /diarrhea /financial difficulties) \[[@B13]\]. The EORTC QLQ-BR23 (coded BR1-BR23), a 23-item breast cancer-specific supplemental module, is meant for use among patients varying in disease stage and treatment modality. The module incorporates five multi-item scales to assess systemic therapy side-effects, arm symptoms, breast symptoms, body image, and sexual functioning. In addition, three single items assess sexual enjoyment, hair loss, and future perspective \[[@B14]\].

The QLQ-BR53 is rated on a four-level Likert scales response system, from 1 "not at all" to 4 "very much." Except for the GHS items, Q29 and Q30, a seven-level Likert scale is used, from 1 "very poor" to 7 "excellent." The time frame of the questionnaires is "during the past week," except for the sexual functioning and sexual enjoyment ("during the past four weeks"). Scales raw scores are calculated by averaging items within scales. The raw score of the participants\' responses are then linearly transformed to a 0--100 score according to the official EORTC scoring manual \[[@B22]\]. The score ranges from 0 to 100, with a higher score indicating a better quality of life for the functioning and GHS but a poorer quality of life for severe symptomatic problems. The GHS scale was used as the overall summary measure, where a high score represents a high overall quality of life. The level of self-assessed GHS helps in predicting survival, which is especially important among survivors to improve the QOL.

For all scales, the raw score, RS, is the mean of the component items:$$\begin{matrix}
{\text{Raw\ Score} = \text{RS} = \frac{\left( {I_{1} + I_{2} + \cdots + I_{n}} \right)}{n}.} \\
\end{matrix}$$

Standard Score, SS, for global health status/functional scales are calculated as$$\begin{matrix}
{\text{SS} = \left\{ { 1 - \frac{\left\{ {\text{RS} - 1} \right\}}{\text{range}}} \right\} \times 100.} \\
\end{matrix}$$

And SS for symptom scales/items are calculated as$$\begin{matrix}
{\text{SS} = \left\{ {\frac{\left\{ {\text{RS} - 1} \right\}}{\text{range}}} \right\} \times 100.} \\
\end{matrix}$$

2.3. Statistical Analysis {#sec2.3}
-------------------------

Descriptive statistics was used to summarize sociodemographic and clinical characteristics of the participants. Normality tests were carried out for QOL scores. As all QOL scores were non-normally distributed, nonparametric tests (i.e., Mann--Whitney U test and Kruskal-Wallis test) were performed to determine whether differences in the mean score of QOL across sociodemographic and clinical parameters of the participants were significant. Differences were considered significant if p value was equal to or less than 0.05.

Regarding aim 1, step-wise multiple linear regression was conducted to investigate the statistically significant predictors associated with global QOL. Regarding aim 2, the Spearman rank correlation coefficients between QLQ-C30 and QLQ-BR23 subscales were firstly calculated, with correlation coefficient \> 0.5 indicating a moderate association and a value \< 0.5 representing a weak association \[[@B23]\]. Next, the latent factor structure was explored by using an exploratory factor analysis (EFA). The number of factors was extracted according to the eigenvalue (i.e., eigenvalue \>1). To account for potential correlations among factors, rotation was performed using an oblique Promax method. Data were analyzed using a SPSS software package (SPSS version 22.0 Inc., Chicago, IL, USA).

3. Results {#sec3}
==========

3.1. Sociodemographic and Clinical Characteristics {#sec3.1}
--------------------------------------------------

Six hundred and twenty-one women patients with confirmed diagnosis of breast cancer were interviewed. Of the total 621 patients, 13 were deleted due to incomplete answers. Finally, a valid sample of 608 patients (97.9%) was analyzed. The full sample sociodemographic and clinical characteristics were presented in [Table 1](#tab1){ref-type="table"}.

3.2. QOL Scores by QLQ-C30 and QLQ-BR23 {#sec3.2}
---------------------------------------

[Table 2](#tab2){ref-type="table"} showed the detailed QOL scores measured by QLQ-C30 and QLQ-BR23. The mean ± standard deviation (SD) score of GHS was 53.8±14.7. Among functional scales, more severe impairments were observed among future perspective (51.5±31.4), body image (64.9±25.0), and social functioning (69.9±24.6). Regarding symptom scales, more severe impairments were observed on insomnia (31.4±24.4), fatigue (34.0±18.1), financial difficulties (34.6±28.7), and upset by hair loss (38.6±30.3).

3.3. QOL Scores by Characteristics of the Participants and the Predictors of Global Health Status (GHS)/QOL {#sec3.3}
-----------------------------------------------------------------------------------------------------------

[Table 3](#tab3){ref-type="table"} presented main differences of QOL scores across clinical characteristics (while more detailed data about QOL by sociodemographic and clinical characteristics can be found in the supplementary materials ([available here](#supplementary-material-1){ref-type="supplementary-material"})). There were no significant differences for both QLQ-C30 and QLQ-BR23 functional scales among patients in different TNM stage. While significant differences were observed in QLQ-C30 symptom scales (including fatigue, nausea and vomiting, pain, dyspnea, appetite loss, and constipation). Patients who received chemotherapy only had lower scores in GHS as well as symptom scales while higher scores in functional scales than those that adopted other types of treatment.

[Table 4](#tab4){ref-type="table"} showed that among patient characteristics (Panel A), age, residence, educational level, employment status, and TNM stage were five statistically significant predictors for GHS. However, when further investigating the factors by the TNM stages, it can be seen that, in early stages (i.e., TNM stages 0-II), age was insignificant and marital status was significant, while, in advanced stages (i.e., TNM stages III-IV), marital status and employment status were insignificant.

The significant functional/symptom subscales which impacted on the global health status were reported in Panels B and C in [Table 4](#tab4){ref-type="table"}. According to the different stages of cancer progressing, the significant scales in QLQ-C30 differed. In early stages, pain, dyspnea, and fatigue were significant, while, in advanced stages, role functioning, cognitive functioning, emotional functioning, nausea and vomiting, pain, and dyspnea were all significantly impacted on the global health status. Among the QLQ-BR23 scales, the same pattern of significant predictors was identified between different stages of breast cancer patients.

3.4. Spearman\'s Rank Correlation and EFA Factor Structure of QLQ-C30 and QLQ-BR23 {#sec3.4}
----------------------------------------------------------------------------------

[Table 5](#tab5){ref-type="table"} showed Spearman\'s rank correlation coefficients between QLQ-C30 and QLQ-BR23 scales. Generally speaking the correlations were weak, with the highest correlation coefficient of 0.428 (between "financial difficulties" in QLQ-C30 and "systemic therapy side-effects" in QLQ-BR23).

The exploratory factor analysis result was reported in [Table 6](#tab6){ref-type="table"}. A total of 10 factors, which explained 61% of the variance, were extracted based on the eigenvalues (eigenvalues\>1; Kaiser-Meyer-Olkin test=0.939; all communalities \>0.34). As can be seen, QLQ-C30 and QLQ-BR23 items are attached to different latent factors, with the only exception observed in the third and fourth factor.

4. Discussion {#sec4}
=============

By conducting a cross-sectional survey with 608 breast cancer patients, this study investigated two important issues that have not been explored in mainland China: what the important functional/symptom scales as well as patient characteristics that contributed to the overall quality of life of breast cancer patients are and whether those scales differ by different stages of cancer progressing and, furthermore, whether each of the QLQ-C30 and QLQ-BR23 provides unique information for the breast cancer patients and thus serves as a complementary measure to each other.

The breast cancer patients in our study had a mean GHS score of 53.8 (SD=14.7), lower than the EORTC QLQ-C30 Reference Values (mean=61.8, SD=24.6) \[[@B24]\], which might be explained by the larger proportion of patients receiving chemotherapy only as the type of treatment in our study (47.4%). It was reported that patients receiving chemotherapy might experience several side-effects that negatively affected their QOL \[[@B25]\]. This was confirmed in our study that patients received chemotherapy reported worse GHS comparing with those undergoing other types of treatment.

In our study, younger patients with a lower educational level reported significantly lower scores in sexual functioning and sexual enjoyment. In addition, the scores of sexual functioning and sexual enjoyment were pretty high comparing with similar researches \[[@B11], [@B26]\]. The findings were not consistent with the previous ones that disrupted sexual functioning or unsatisfactory sexual life was related to poorer HRQOL at younger age, treatment with chemotherapy, and emotional distress \[[@B27]--[@B29]\]. There might be an overestimation and the main potential reason may be the unique culture background. Sexuality is considered a private topic and is not openly discussed in public in China \[[@B30]\]. Thus, Chinese women are more conservative about the sex-related topics; the older or the lower-educated patients are more likely to avoid answering these questions or choose a random answer. As a disease closely related to women\'s identities, breast cancer affected the perception of sexuality and their own personal image \[[@B29]\]. Therefore, more attention should be paid to Chinese women with breast cancer on sexual problems.

Age, residence, educational level, employment status, and TNM stage were five significant predictors for overall quality of life according to the result of multiple linear regression. According to Wong-Kim et al., after being diagnosed with breast cancer, the Chinese women were more concerned about survival and may put a greater emphasis on recuperating from their illness rather than worrying about body image and their marital relationship. But, for traditional Chinese women, they did not want to burden their families with their deteriorating health \[[@B31]\]. What is more, patients with early breast cancer may be concerned about premature menopause leading to loss of fertility, recurrence, body image, and sexuality \[[@B32], [@B33]\], which could have a negative effect on their overall quality of life. Generally, better GHS scores were found in patients with stable job security, who were more likely to seek access to information and resources for problem solving. And they could be more compliant with the therapeutic regime because they had little problem in financial difficulties and felt more secure. However, when further investigating the factors by TNM stages, age was insignificant for early stage patients (TNM stages 0--II), and marital and employment status were insignificant for patients in advanced stages (TNM stages III-IV). The certain reasons were not clear at present, which remains to be discussed. Qualitative research can be considered to be applied to investigate the potential reasons in the future.

According to the different stages of cancer progressing, the significant subscales differed. For all patients, an increased level of systemic therapy side-effect was linked to a decrease on GHS score. Increased levels of pain and fatigue were associated with a 0.107 and 0.212 GHS score decreased for early stage patients, and increased levels of role and cognitive functioning were associated with a 0.119 and 0.211 GHS score increased for advanced stage patients. These findings were consistent with former studies that treatment side-effects (even those of lower grade) may induce symptoms such as nausea and vomiting, pain, and fatigue, which are not life-threatening but can adversely impact patients\' well-being and are associated with worse HRQOL \[[@B34]\]. While an increased level of sexual enjoyment associated with a decrease on GHS score and the aggravation of dyspnea associated with an increase on GHS score were inconsistent with our common sense. The subjective perception of HRQOL might not necessarily be in accordance with relevant clinical factors \[[@B35]\]. Patients\' expectation might change with time and psychological response to breast cancer might be independent of cancer stage \[[@B36]\]. If a person is confronting an incurable condition their values will shift and patients certainly assign different values to hypothetical health states than outsiders \[[@B20]\]. Therefore, more attention should be paid to improve patients\' HRQOL through dealing with the particular impaired function or symptom for it has been quite difficult to extend lifespan for the advanced breast cancers or the long-term survivors.

This study also investigated the complementary roles between two EORTC questionnaires in breast cancer. The correlation and factor analysis have been used to confirm the construct and criterion-related validity of the simplified Chinese version of the QLQ-BR53; however, the factor analyses were applied separately to QLQ-C30 and QLQ-BR23 \[[@B18], [@B19]\]. In our study, Spearman\'s rank correlation and an EFA analysis were used to assess the degree of conceptual overlap between QLQ-C30 and QLQ-BR23. The results showed that there were only weak correlations between the two QOL instruments of EORTC QLQ-C30 and QLQ-BR23. The EFA results showed cumulative contribution rates \> 61%, indicating a good extraction effect. Ten common factors extracted were not completely conformed to the theory structure of the EOTRC QLQ-BR53 scales, but the EFA results mostly confirmed the original scoring algorithm. Among 10 latent factors, only factors 3 and 4 were composed of both QLQ-C30 items and one QLQ-BR23 item, further confirming a complementary role between these two questionnaires.

This study has two main limitations. Firstly, the patients were recruited from eastern China and the conclusions may not be applicable to the whole Chinese populations. Second, this was a cross-sectional study. It will be important to further assess the changes on HRQOL using a longitudinal survey design.

In conclusion, clinical characteristics are relevant factors influencing the QOL of women breast cancer patients in eastern China. Age, residence, educational level, employment status, and TNM stage were five significant predictors for GHS. Pain, dyspnea, sexual enjoyment, and systemic therapy side-effect were main subscales which had a significant impact on the global health status for all patients. As complementary questionnaires, it is recommended that the EORTC QLQ-C30 and QLQ-BR23 should be applied to assess HRQOL at the same time. The results of this study enriched our understanding of using EORTC QLQ-C30 and QLQ-BR23 questionnaires in China.
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###### 

More detailed data about quality of life scores by sociodemographic and clinical characteristics of the participants were displayed in the supplementary materials. Differences in the mean score of quality of life across sociodemographic and clinical parameters of the participants were considered significant if p value was equal to or less than 0.05. Table S1: quality of life scores by age, residence (house locality), and marital status; Table S2: quality of life scores by educational level and medical security; Table S3: quality of life scores by annual household income and disease duration; Table S4: quality of life scores by metastatic breast cancer state (State M) and menopausal status.

###### 

Click here for additional data file.

###### 

Sociodemographic and clinical characteristics of the participants (n=608).

  **Characteristics**                                 **Number**   **Percentage (**%**)**
  --------------------------------------------------- ------------ ------------------------
  **Age (Mean=48.0, SD=9.6)**                                       
   \<45                                               220          36.2
   45-54                                              224          36.8
   ≥55                                                164          27.0
  **Residence(house locality)**                                     
   Rural                                              299          49.2
   Urban                                              309          50.8
  **Marital status**                                                
   Single                                             27           4.4
   Married                                            539          88.7
   Divorced/Widow                                     42           6.9
  **Employment status**                                             
   Urban employee                                     396          65.1
   Peasants                                           156          25.7
   Unemployment                                       47           7.7
   Others                                             9            1.5
  **Educational level**                                             
   Illiteracy or Primary school                       200          32.9
   Secondary school                                   128          21.1
   High school/technical secondary school             131          21.5
   University degree and above                        149          24.5
  **Annual household income (Chinese Yuan, CNY)**                   
   \<30,000                                           161          26.5
   30,000-80,000                                      262          43.1
   80,001-150,000                                     153          25.2
   \>150,000                                          32           5.2
  **Metastatic breast cancer state (State M)**                      
   Yes                                                141          23.2
   No                                                 467          76.8
  **TNM Stage**                                                     
   0-I                                                175          28.8
   II                                                 142          23.4
   III                                                218          35.8
   IV                                                 73           12.0
  **Disease duration, months (Mean=38.2, SD=40.9)**                 
   ≤12                                                190          31.2
   13-36                                              197          32.4
   37-60                                              112          18.4
   ≥61                                                109          18.0
  **Menopausal Status**                                             
   Pre-menopausal                                     274          45.1
   Post-menopausal                                    334          54.9
  **Type of treatment**                                             
   Chemotherapy only                                  288          47.4
   Others                                             320          52.6

**Note:**

TNM: tumor, node, and metastases classification of malignant tumors.

Exchange rate: according to the Organization for Economic Cooperation and Development (OECD) data ([https://data.oecd.org/conversion/exchange-](https://data.oecd.org/conversion/exchange-rates.htm)

[rates.htm](https://data.oecd.org/conversion/exchange-rates.htm)), the average annual exchange rate between US\$ and CNY in 2014 was US\$1 = CNY 6.143, and in 2015 it was US\$1 = CNY 6.227.

###### 

Quality of life scores for all participants (n=608).

  **EORTC Item**                        **Mean score**   **SD**   **Median**
  ------------------------------------- ---------------- -------- ------------
  **Panel A: QLQ-C30 Questionnaire**                              
                                                                  
  **Global Health Status**              53.8             14.7     50.0
  **Functional Scales**                                            
   Physical functioning                 75.5             17.2     80.0
   Role functioning                     77.4             25.5     83.3
   Emotional functioning                74.2             19.7     75.0
   Cognitive functioning                76.9             19.5     83.3
   Social functioning                   69.9             24.6     66.7
  **Symptom Scales**                                               
   Fatigue                              34.0             18.1     33.3
   Nausea and vomiting                  19.0             21.5     16.7
   Diarrhoea                            10.4             18.9     0.0
   Financial difficulties               34.6             28.7     33.3
   Pain                                 28.9             19.9     33.3
   Dyspnoea                             17.2             22.2     0.0
   Insomnia                             31.4             24.4     33.3
   Appetite loss                        24.1             25.3     33.3
   Constipation                         24.6             26.4     33.3
                                                                  
  **Panel B: QLQ-BR23 Questionnaire**                             
                                                                  
  **Functional Scales**                                            
   Body image                           64.9             25.0     66.7
   Sexual functioning                   89.0             15.9     100.0
   Future perspective                   51.5             31.4     66.7
   Sexual enjoyment                     88.3             19.6     100.0
  **Symptom Scales**                                               
   Systemic therapy side effects        24.7             16.9     23.8
   Breast symptoms                      17.1             19.8     8.3
   Arm symptoms                         20.2             19.6     16.7
   Upset by hair loss                   38.6             30.3     33.3

SD, standard deviation

###### 

Quality of life scores (mean ± SD) by TNM stage, type of treatment.

  **EORTC Items**                       **TNM stage**   **P**       **Type of treatment**   **P**                                             
  ------------------------------------- --------------- ----------- ----------------------- ----------- ------------- ----------- ----------- ---------------
  **Panel A: QLQ-C30 Questionnaire**                                                                                                          
                                                                                                                                              
   GHS                                  55.1±13.3       54.0±15.8   52.6±15.1               53.9±14.0   0.497         51.8±12.8   55.6±15.9   \<0.001^*∗*^ 
  **Functional scales**                                                                                                                        
   PF                                   75.5±17.2       78.5±15.1   74.4±18.0               73.0±18.4   0.068         78.5±16.2   72.8±17.7   \<0.001^*∗*^ 
   RF                                   76.9±25.0       81.1±25.2   76.2±25.4               74.4±27.5   0.112         81.0±23.3   74.1±27.0   0.001^*∗*^ 
   EF                                   75.0±18.3       77.0±19.5   72.3±20.6               72.7±20.3   0.170         75.9±18.7   72.7±20.5   0.052
   CF                                   78.2±18.1       79.2±17.4   74.8±21.8               75.3±18.7   0.303         79.0±18.3   74.9±20.3   0.012^*∗*^ 
   SF                                   71.5±25.8       71.8±22.8   68.6±25.3               66.2±22.6   0.180         71.5±23.5   68.5±25.5   0.118
  **Symptom scales**                                                                                                                           
   FA                                   34.4±16.4       30.9±18.3   35.0±18.5               36.2±19.8   0.017^*∗*^    32.0±16.1   35.8±19.5   0.016^*∗*^ 
   NV                                   19.5±21.2       14.0±18.6   20.9±23.2               21.7±20.7   0.010^*∗*^    15.0±19.1   22.6±22.8   \<0.001^*∗*^ 
   DI                                   10.5±18.2       7.5±16.1    12.2±21.5               10.5±16.5   0.211         7.5±16.0    13.0±20.8   0.001^*∗*^ 
   FI                                   33.9±31.0       33.6±28.0   35.0±27.6               37.4±27.7   0.568         33.6±26.8   35.6±30.2   0.545
   PA                                   29.4±18.8       25.0±19.5   30.3±20.6               30.8±20.0   0.025^*∗*^    26.1±18.7   31.3±20.5   0.001^*∗*^ 
   DY                                   17.9±21.7       12.2±18.0   19.1±23.7               19.6±25.4   0.039^*∗*^    12.7±19.3   21.2±23.9   \<0.001^*∗*^ 
   SL                                   32.2±24.2       26.8±22.5   32.7±24.6               34.7±26.9   0.092         30.2±24.1   32.5±24.6   0.225
   AP                                   23.6±23.4       18.3±23.0   26.6±26.7               28.8±27.9   0.009^*∗*^    21.5±23.4   26.3±26.7   0.038^*∗*^ 
   CO                                   26.5±26.6       19.0±23.3   26.6±28.0               25.1±25.3   0.048^*∗*^    23.0±26.1   26.0±26.6   0.136
                                                                                                                                              
  **Panel B: QLQ-BR23 Questionnaire**                                                                                                         
                                                                                                                                              
  **Functional scales**                                                                                                                        
   BRBI                                 65.2±24.3       67.6±26.4   62.9±24.8               64.8±24.4   0.355         65.9±25.9   64.0±24.2   0.090
   BRSEF                                87.1±16.5       91.1±15.7   89.2±15.7               88.6±15.2   0.081         92.4±14.0   85.9±16.9   \<0.001^*∗*^ 
   BRFU                                 51.0±31.5       53.5±33.9   49.7±30.9               53.9±27.6   0.600         51.4±30.8   51.6±32.0   0.902
   BRSEE                                87.5±18.1       91.2±17.8   87.6±21.6               87.2±19.7   0.153         92.8±14.6   84.3±22.4   \<0.001^*∗*^ 
  **Symptom scales**                                                                                                                           
   BRST                                 24.8±16.2       21.8±15.7   26.5±17.8               24.8±17.1   0.097         23.0±15.6   26.3±17.8   0.023^*∗*^ 
   BRBS                                 17.1±18.6       13.2±16.9   18.6±21.5               20.3±21.8   0.075         14.6±19.5   19.4±19.8   \<0.001^*∗*^ 
   BRAS                                 20.4±18.4       17.2±18.5   20.7±20.8               24.2±20.6   0.083         17.8±19.6   22.4±19.4   0.001^*∗*^ 
   BRHL                                 38.6±30.5       37.8±32.1   40.3±29.9               34.7±27.3   0.562         39.7±30.3   37.6±30.3   0.450

SD, standard deviation.

GHS, global health status; PF, physical functioning; RF, role functioning; EF, emotional functioning; CF, cognitive functioning.

SF, social functioning; FA, fatigue; NV, nausea and vomiting; DI, diarrhoea; FI, financial difficulties; PA, pain; DY, dyspnoea.

SL, insomnia; AP, appetite loss; CO, constipation; BRBI, body image; BRSEF, sexual functioning; BRFU, future perspective.

BRSEE, sexual enjoyment; BRST, systemic therapy side effect; BRBS, breast symptoms; BRAS, arm symptoms; BRHL, upset by hair loss.

###### 

Final model of predictors for Global Health Status scores.

                                                            **GHS of all participants**   **GHS of patients in TNM Stage 0--II**   **GHS of patients in TNM Stage III-IV**
  --------------------------------------------------------- ----------------------------- ---------------------------------------- -----------------------------------------
                                                            **Coefficient (SE)**          **Coefficient (SE)**                     **Coefficient (SE)**
                                                                                                                                   
  **Panel A: Patient characteristics**                                                                                              
                                                                                                                                   
  **(Constant)**                                            87.720(5.150)^*∗∗*^           102.608(6.136)^*∗∗*^                     64.272(7.553)^*∗∗*^ 
  **Age**                                                   -0.146(0.053)^*∗*^            -0.039(-0.774)                           -0.183(0.071)^*∗*^ 
  **Residence (ref: urban)**                                                                                                        
   rural                                                    5.454(1.220)^*∗∗*^            5.848(1.834)^*∗*^                        2.920(1.365)^*∗*^ 
  **Marital status (ref: single)**                                                                                                  
   Married                                                  -0.047(-1.295)                -15.586(4.604)^*∗*^                      -0.001(-0.015)
   Divorced/widow                                           -0.023(-0.660)                -14.775(5.079)^*∗*^                      -0.025(-0.506)
  **Educational level (ref: illiteracy /primary school)**                                                                           
   Secondary school                                         -0.020(-0.582)                -0.034(-0.673)                           0.024(0.509)
   High school/technical secondary school                   0.043(1.098)                  0.085(1.461)                             0.046(0.906)
   university degree and above                              6.432(1.275)^*∗∗*^            5.418(1.920)^*∗*^                        8.956(1.699)^*∗∗*^ 
  **Employment status (ref: urban employee)**                                                                                       
   peasants                                                 -4.947(1.395)^*∗∗*^           -4.515(1.898)^*∗*^                       -0.099(-1.877)
   unemployment                                             -4.336(1.984)^*∗*^            -0.092(-1.791)                           -0.029(-0.647)
   others                                                   -0.037(-1.134)                -0.019(-0.395)                           -0.010(-0.222)
  **TNM Stage (ref: 0-II)**                                                                                                         
   III-IV                                                   -1.912(0.952)^*∗*^            **------**                               **------**
                                                                                                                                   
  **Panel B: QLQ-C30 scales**                                                                                                       
                                                                                                                                   
   Role functioning                                         0.081(0.028)^*∗*^             0.050(0.711)                             0.119(0.039)^*∗*^ 
   Cognitive functioning                                    0.077(1.520)                  0.035(0.510)                             0.211(0.058)^*∗∗*^ 
   Emotional functioning                                    -0.066(-1.392)                -0.047(-0.720)                           -0.131(0.056)^*∗*^ 
   Nausea and vomiting                                      0.046(1.017)                  -0.056(-0.874)                           0.099(0.042)^*∗*^ 
   Pain                                                     -0.125(0.038)^*∗*^            -0.107(0.050)^*∗*^                       -0.140(0.055)^*∗*^ 
   Dyspnoea                                                 0.128 (0.027)^*∗∗*^           0.123(0.042)^*∗*^                        0.104(0.035)^*∗*^ 
   Fatigue                                                  -0.135(0.043)^*∗*^            -0.212(0.058)^*∗∗*^                      -0.130(-1.771)
   insomnia                                                 -0.049(0.023)^*∗*^            -0.037(-0.670)                           -0.082(-1.507)
                                                                                                                                   
  **Panel C: QLQ-BR23 scales**                                                                                                      
                                                                                                                                   
   Sexual enjoyment                                         -0.230(0.027)^*∗∗*^           -0.273(0.041)^*∗∗*^                      -0.194(0.035)^*∗∗*^ 
   systemic therapy side effect                             -0.213(0.042)^*∗∗*^           -0.144(0.050)^*∗*^                       -0.185(0.055)^*∗*^ 
   Arm symptoms                                             0.078(0.034)^*∗*^             0.107(1.711)                             0.120(1.912)
   Body image                                               -0.053(0.025)^*∗*^            -0.075(-1.223)                           -0.092(-1.609)

**Note:**stepwise regression was applied in the multiple linear regression analysis; a constant was included in each model.

SE, Standard Error; *∗∗* and *∗* indicate P \< 0.01 and P \< 0.05, respectively.

###### 

Spearman\'s rank correlation coefficients among QLQ-C30 and QLQ-BR23 scales.

  **QLQ-C30**                                                                                                                                                                                                      
  -------------------- ----------------------- ---------- ----------------------- -------------------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- --------
                                               **GHS**    **Functional scales**   **Symptom scales**                                                                                                               
                                                          **PF**                  **RF**               **EF**   **CF**   **SF**   **FA**   **NV**   **DI**   **FI**   **PA**   **DY**   **SL**   **AP**   **CO**   
                                                                                                                                                                                                                   
  **QLQ-BR23**         **Functional scales**   **BRBI**   0.021                   0.149                0.088    0.111    0.129    0.011    -0.083   -0.060   -0.066   -0.376   -0.019   -0.103   -0.033   -0.066   -0.012
  **BRSEF**            -0.349                  0.192      0.206                   0.172                0.186    0.154    -0.159   -0.210   -0.087   -0.212   -0.176   -0.149   -0.124   -0.193   -0.067            
  **BRFU**             0.056                   0.155      0.040                   0.097                0.094    0.014    -0.065   -0.075   -0.109   -0.371   -0.017   -0.125   -0.012   -0.041   -0.058            
  **BRSEE**            -0.383                  0.224      0.247                   0.194                0.217    0.181    -0.188   -0.188   -0.073   -0.215   -0.222   -0.178   -0.125   -0.201   -0.079            
  **Symptom scales**   **BRST**                -0.138     -0.155                  -0.103               -0.106   -0.134   -0.034   0.080    0.106    0.063    0.428    0.056    0.092    0.022    0.065    0.023    
  **BRBS**             0.058                   -0.250     -0.237                  -0.204               -0.198   -0.121   0.195    0.145    0.049    0.350    0.170    0.177    0.066    0.179    0.029             
  **BRAS**             0.019                   -0.235     -0.200                  -0.187               -0.170   -0.131   0.158    0.116    0.090    0.412    0.097    0.129    0.025    0.094    0.010             
  **BRHL**             -0.215                  -0.098     -0.018                  -0.040               -0.059   0.016    0.036    0.014    0.041    0.289    -0.023   0.057    0.013    0.001    0.022             

**Note:**p\<0.01.

GHS, global health status; PF, physical functioning; RF, role functioning; EF, emotional functioning; CF, cognitive functioning.

SF, social functioning; FA, fatigue; NV, nausea and vomiting; DI, diarrhoea; FI, financial difficulties; PA, pain; DY, dyspnoea.

SL, insomnia; AP, appetite loss; CO, constipation; BRBI, body image; BRSEF, sexual functioning; BRFU, future perspective.

BRSEE, sexual enjoyment; BRST, systemic therapy side effect; BRBS, breast symptoms; BRAS, arm symptoms; BRHL, upset by hair loss.

###### 

Exploratory factor analysis (pattern matrix).

             **Factor Loadings**                                                                    
  ---------- --------------------- ------- ------- ------- ------- ------- ------- -------- ------- -------
  **BR12**   0.952                                                                                   
  **BR11**   0.942                                                                                   
  **BR10**   0.870                                                                                   
  **BR9**    0.769                                                                                   
  **BR13**   0.637                                                                                   
  **BR8**    0.352                         0.349                                                     
  **BR5**                                                                                            
  **BR23**                         0.921                                                             
  **BR21**                         0.907                                                             
  **BR20**                         0.897                                                             
  **BR22**                         0.865                                                             
  **BR18**                         0.598                                                            0.365
  **BR19**                         0.591                                                             
  **BR17**                         0.525           0.311                                             
  **Q14**                                  0.854                                                     
  **Q15**                                  0.770                                                     
  **Q13**                                  0.668                                                     
  **Q16**                                  0.641                                                     
  **Q17**                                  0.478                                                     
  **BR7**                                  0.404                                                     
  **Q11**                                  0.403                                                     
  **Q12**                                  0.382   0.327                                             
  **Q6**                                           0.930                                             
  **Q7**                                           0.896                                             
  **Q5**                                   0.327   0.490                                             
  **Q2**                                           0.470                                             
  **Q3**                                   0.336   0.458                                             
  **Q8**                                   0.364   0.452                                             
  **Q10**                                          0.429                                             
  **Q4**                                           0.397                                             
  **Q1**                                           0.382                                             
  **Q9**                                           0.334                                             
  **Q27**                                                  0.910                                     
  **Q28**                                                  0.845                                     
  **Q26**                                                  0.817                                     
  **Q24**                                                  0.477                                     
  **Q25**                                                  0.440                                    
  **Q21**                                                          0.893                             
  **Q22**                                                          0.857                             
  **Q23**                                                          0.777                             
  **Q20**                                                          0.534                             
  **Q19**                                                          0.398                             
  **Q18**                                                          0.324                             
  **BR15**                                                                 0.900                     
  **BR14**                                                                 0.863                     
  **BR16**                                                                 0.382                     
  **Q29**                                                                          -0.918            
  **Q30**                                                                          -0.859            
  **BR1**                                                                                   0.775    
  **BR2**                                                                                   0.767    
  **BR3**                                                                                   0.637    
  **BR4**                                                                                           0.537
  **BR6**                                                                                           0.508

***Note*.**extraction method: maximum likelihood. Rotation method: Promax with Kaiser normalization.

Loadings below 0.30 were not shown.

[^1]: Academic Editor: Abdelaziz M. Thabet
